Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Gets European Rights to Arcturus TUO-gene Profile

NEW YORK, Feb. 2 (GenomeWeb News) - Agendia, a Dutch firm that specializes in gene-expression services, has signed an agreement with Arcturus Bioscience to license the company's exclusive European rights to its Tumor of Unknown Origin(TUO)-gene expression profile, the companies said today.

 

Agendia said that it had used Arcturus' profile to create a gene expression-based diagnostic test called CupPrint.

 

The new test will be used in helping doctors locate the primary tumors in cancer patients.

 

René Bernards , co-founder and chief scientific officer of Agendia, said in a statement that the new tool will have an impact in treating patients that often face higher mortality rates because their primary tumors cannot be rapidly identified.

 

According to Agendia, CupPrint uses a gene-expression database of currently 32 different tissue types and 78 tumor types, and can therefore rapidly determine whether the primary tumor belongs to one of the major categories.

 

CupPrint will be available in early spring, Bernards said. The financial details of the deal were not disclosed.

 

Bernhard Sixt, Agendia's CEO, said the company's "aim is to develop products that assist oncologists and physicians to determine who should be treated in which specific way. Targeted, tailor-made clinical treatments plans are essential in maximizing a patient's chances of a cure."

 

Agendia is based in Amsterdam. Arcturus Bioscience is headquartered in Mountain View, Calif.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.